Ciprofloxacin (GMP)

Overview

Ciprofloxacin GMP is Ciprofloxacin ( HY-B0356 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV . Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.

Application

Products | Products > GMP Small Molecules | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Periodontal Disease | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Topoisomerase | Products > Signaling Pathways > Akt | Products > Signaling Pathways > β-catenin

Product Information

• Catalog No.: HY-B0356G
• CAS No.: 85721-33-1
• Molecular Formula: C17H18FN3O3
• Molecular Weight: 331.34
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source